Introduction
When the genome of organisms becomes damaged, checkpoint mechanisms ensure that the damage is detected and removed (Lengauer et al., 1998) . This can occur either through cell cycle arrest and repair, permanent senescence, or apoptosis (Itahana et al., 2001; Offer et al., 2002; Chavez-Reyes et al., 2003) . The most prominent checkpoint in this respect is p53 (Vogelstein et al., 2000) . DNA damage can come about though environmental factors (such as radiation), or through the generation of metabolic byproducts as a consequence of ageing (Finkel and Holbrook, 2000) . The induction of checkpoints upon damage has two potential consequences. First, it ensures that the genome of cells remains stable and that cells do not acquire genetic alterations which can lead to the development of cancer (Campisi, 2003; Hasty et al., 2003; Oren, 2003; Schmitt, 2003) . Cancers are characterized by the inactivation of checkpoint genes. About half of all human cancers show a loss of p53 (Vogelstein et al., 2000) . On the other hand, the induction of checkpoints can result in symptoms of ageing (Campisi, 2003; Hasty et al., 2003; Oren, 2003; Schmitt, 2003) . If the genome experiences damage at a relatively high rate, frequent cell cycle arrest or apoptosis can reduce tissue function and can thus contribute to ageing.
Before discussing this topic further, it is important to define the concept of ageing in the current context. Ageing is a complex phenomenon and involves many different aspects. This paper concentrates on the relationship between ageing, checkpoint genes, and cancer. Ageing is intricately linked to the generation of metabolic byproducts which can cause DNA damage. This damage is in turn detected by checkpoint genes, resulting in cell cycle arrest, senescence, or apoptosis. These mechanisms lead to a reduction in the number of functional tissue cells. For the current context, ageing is defined by a reduction in tissue function brought about by DNA damage. On a more physical level, this can translate into the weight of an organism or of specific organs. Such criteria of ageing have been used in experiments with mice which examined the relationship between p53 and ageing (Tyner et al., 2002) , and which will be discussed extensively later.
The relationship between checkpoint competence, senescence, and cancer is complex. How does a reduction or an increase in checkpoint competence affect cancer incidence, cancer progression, and the development of age-related symptoms? Here, mathematical models are developed in order to investigate this question. They take into account two basic populations of cells: tissue cells which are not cancerous, and cancer cells. Recent data indicate that interactions between tissue cells and tumor cells are crucial for the ability of a cancer to become established and progress (Hsu et al., 2002; Mueller and Fusenig, 2002) . The mathematical models take into account such interactions and concentrate especially on inhibitory effects which tissue cells can exert on cancer cells. Two parameter regions are identified. (i) A reduction of checkpoint competence can reduce the onset of age-related symptoms in the face of DNA damage, but will increase the rate of cancer initiation and progression. (ii) On the other hand, a reduction of checkpoint competence can lead to both a reduced onset of age-related symptoms, and a reduced incidence of cancer. While the model suggests that fewer cancers are generated as a result of reduced checkpoint competence in this parameter region, it further suggests that the cancers which do become established progress at an accelerated rate. These results are counterintuitive, but are supported by experimental data in the context of p53.
Results
We consider a mathematical model which takes into account both the population of healthy tissue cells, and the population of first-stage tumor cells. The basic difference between these two is that the population size of healthy cells is constant, while the population of tumor cells can clonally expand. The central concept of the model is as follows. It starts with healthy tissue, which experiences a certain amount of genome damage. This is either repaired or not depending on checkpoint competence. In the absence of repair, and if the mutation does not result in apoptosis, a transformed cell can be generated with a certain probability (first stage tumor cell). This tumor cell can expand and grow to a certain limited size. The model examines the average time it takes for the number of tumor cells to increase to a defined value. The model does not consider growth of the tumor beyond this first stage. It does, however, examine the rate with which this first-stage tumor can acquire additional mutations; this is a measure for the ability of the tumor to progress towards more advanced stages. The model is explained schematically in Figure 1 . The general question which will be examined is as follows. How does a reduction in checkpoint competence influence the initiation and progression of tumors? The model is built and investigated in the following sections.
Healthy tissue dynamics
We start with the population of healthy cells. We distinguish between two subpopulations: functioning cells, x, and arrested cells, y. The DNA of cells is damaged with a probability u, which correlates with the application of carcinogenic agents. With a probability Z, this damage results in cell cycle arrest. The arrested cell repairs the DNA damage and returns to a functioning state at a rate g. The lower the value of g, the longer the duration of cell cycle arrest. If g ¼ 0, there is indefinite senescence. With a probability 1ÀZ, the DNA damage does not result in cell cycle arrest and repair. Now there are two possibilities. With a probability a, the damage leads to cell death, for example, as a result of apoptosis.
With a probability 1Àa, the damaged or mutated cell survives. With a probability b the mutation is carcinogenic; that is, a transformed cell is generated. With a probability 1Àb the mutation does not contribute to the process of carcinogenesis. For simplicity it is assumed that these cells are selectively neutral.
Therefore, checkpoint competence is captured in two parameters. The parameter Z describes the probability that damage will result in cell cycle arrest and repair. The parameter a describes the probability that damage results in apoptosis. The value of these parameters can range between zero and one. A lower value of Z corresponds to a lower probability of arrest and repair in all cells and could in practical terms correspond to, for example, a p53 knockout organism. If Z ¼ 0, damage is never repaired. If Z ¼ 1, repair always happens upon damage and mutations can never occur. The same applies to the probability to undergo apoptosis upon DNA damage.
These dynamics are given by the following set of differential equations which describe the development of the cell populations over time.
The parameter r denotes the turnover rate of the cells, and f is an expression which ensures that the population size x þ y remains constant
. These dynamics reach a steady state where both functioning and arrested cells are present. The frequencies of functioning and arrested cells are determined mainly by the rate at which DNA is damaged, u, the probability that DNA damage results in arrest, Z, and the duration of cell cycle arrest, g. (Expressions for these frequencies are not written out here because they are complicated and un-informative.) A higher rate of DNA damage (higher value of u), a higher probability of arrest (higher value of Z), and a longer duration of cell cycle arrest (lower value of g) correlate with a lower fraction of functional cells (Figure 2 ). The effect of apoptosis on the number of tissue cells is difficult to determine. In the basic model as it is written here, tissue size is assumed to remain constant through homeostatic regulation. If cells die, the tissue compensates by producing more cells. Therefore, apoptosis does not have an effect on tissue size in this setting. During ageing, however, it is likely that the ability of the tissue to renew itself becomes compromised. In this context, increased occurrence of apoptosis upon DNA damage can lead to a reduction in the number of functioning tissue cells, in the same manner as shown for the induction of cell cycle arrest. As the relationship between ageing and apoptosis is currently unclear (Jansen-Durr, 2002; Campisi, 2003; Camplejohn et al., 2003; Gilhar et al., 2004) , and because the processes of cell renewal and proliferation upon death may also vary among different tissues, the Checkpoint genes, ageing, and cancer D Wodarz effect of apoptosis will not be analysed explicitly. Instead, the analysis concentrates on how the induction of cellular senescence influences the relationship between a decline in tissue function and the emergence of cancer (Campisi, 2001; Parrinello et al., 2003) .
Tumor cell dynamics
Next, consider the population of tumor cells. In addition to the basic cellular process which has been described in the context of healthy cells, the tumor cell dynamics are characterized by some important additional features. The tumor cells escape homeostatic regulation and undergo clonal expansion rather than staying at a constant population size. In addition, the proliferation of tumor cells can be inhibited by the tissue microenvironment. This is a well-documented process (Hsu et al., 2002; Mueller and Fusenig, 2002) and is explained in more detail before the model is constructed and analysed. Experiments strongly suggest that the genetic and molecular events which occur in cancerous cells are not sufficient to account for the process of carcinogenesis. In addition, the microenvironment in which the cancer develops may be equally important for the tumor cells to escape homeostatic control and to give rise to disease (Tlsty, 2001; Tlsty and Hein, 2001 Damaged cells can either repair with a probability Z, or fail to repair the damage with a probability 1ÀZ. Repair results in cell cycle arrest, and arrested cells return to a functional or dividing state with a rate g. Mutations which are not repaired are lethal (e.g. by apoptosis) with a probability a and survive with a probability (1Àa). With a rate b(1Àa) the damage results in a mutation, which transforms the healthy cell into a first stage tumor cell. The population of first-stage tumor cells undergoes clonal expansion. Otherwise, the tumor cell cycle involves the same basic processes as the cell cycle of healthy cells. As I consider checkpoints which are lost at later stages of cancer progression (such as p53), the first-stage tumor cells are again characterized by arrest and apoptosis upon damage. Further mutations can give rise to more carcinogenic mutations. (b) Dynamics which underlie the equations. The model starts with a population of normal tissue cells that are characterized by a certain checkpoint competence, defined by the parameters Z and a. Low checkpoint competence correlates with organisms which are deficient in the checkpoint under consideration (e.g. p53À/À). They remain at a constant size. A genomic alteration which is not repaired and not lethal can result in the generation of a transformed cell (first-stage tumor cell). This tumor cell population is assumed to undergo a phase of clonal expansion to give rise to a detectable tumor. At this point, it is assumed that growth stops. Further progression of this first-stage tumor (e.g. resulting in loss of the checkpoint) requires the accumulation of additional mutations. This mutation rate is assumed to correlate with the ability of the tumor to progress towards malignancy. The initial phase of clonal expansion is assumed to be inhibited by tissue cells with a rate p. As explained in the text, such inhibitory effects are well documented in the literature, and the most prominent example is the inhibition of angiogenesis
Checkpoint genes, ageing, and cancer D Wodarz surrounding the tumors shows in many cases changes in the patterns of gene expression, cellular composition, and the extracellular matrix. This allows cancers to grow and progress. The development of cancer can thus be seen as a conspiracy between tumor cells and their altered environment, which allows uncontrolled growth. Under nonpathogenic conditions, the tissue environment can prevent tumor cells from growing to significant levels. Autopsies have revealed that multiple small and nonpathogenic tumors exist, which have failed to progress (Folkman and Kalluri, 2004) . A major regulatory force in this context is the inhibition of angiogenesis, that is, the formation of new blood supply which tumor cells need to proliferate (Bayko et al., 1998; Hahnfeldt et al., 1999; Folkman, 2002) . Angiogenesis inhibitors are produced by normal tissue cells, but also by tumor cells. The tumor can only progress if it attains mutations which allow for the production of a sufficient level of angiogenesis promoters, such that inhibition is overcome and new blood supply is built. Other, less well-defined mechanisms of tumor cell inhibition have also been reported (Guba et al., 2001 ). Here we focus on inhibitory effects which the tissue microenvironment can exert on tumor cells, and examine how this influences the relationship between checkpoint gene competence, ageing, and the development of cancer. Similarly as before, the model distinguishes between dividing cells, w, and arrested cells, z. These dynamics are captured in the following pair of differential equations which describe the development of the tumor cells over time:
The first term in the equation for tumor growth represents the production of tumor cells from healthy cells by mutation with a rate brxu(1ÀZ)(1Àa). In words, a transformed cell is generated when a healthy cell experiences a genomic alteration which is not repaired, is carcinogenic, and does not result in apoptosis. The parameter r denotes the turnover of the tumor cells. Note the absence of the parameter f, which means that there is no constant population size. Instead, the population of tumor cells can grow exponentially. Similarly to healthy cells, tumor cells can become damaged with a rate u. With a probability Z, the damage results in cell cycle arrest and arrested cells return to a dividing state with a rate g. With a probability 1ÀZ, damage does not result in cell cycle arrest and repair. With a probability a, the damage leads to cell death, for example, caused by apoptosis. With a probability 1Àa, the damaged cell survives and attains an additional mutation. This mutation contributes to further cancer progression with a probability b. In addition to these basic cell growth kinetics, the model Figure 2 The fraction of functional tissue cells is a function of the rate at which DNA becomes damaged (u), checkpoint competence (the probability to arrest upon damage, Z), and the duration of cell cycle arrest (expressed as the rate at which cells exit from the arrested state, g). A higher rate of DNA damage (higher value of u), a higher probability to enter cell cycle arrest (higher value of Z), and a longer duration of cell cycle arrest (lower value of g) result in a reduced fraction of functional tissue cells. Parameter values were chosen as follows. r ¼ 2;
Checkpoint genes, ageing, and cancer D Wodarz assumes that tumor cell division is inhibited by the surrounding tissue cells with a rate p. The higher the value of p, the lower the rate of tumor cell division. If the value of p is sufficiently large, the rate of tumor cell division is less than or equal to the tumor death rate; hence, the tumor fails to grow altogether. In the model, only cells which do not repair or are not senescent can contribute to this suppressive activity. This is because repairing or senescent cells are not active. Note that the outcome of the model does not depend on the particular form by which tissue-mediated tumor cell inhibition is described. Alternatives (such as a tissue-mediated increase in the death rate of tumor cells) have also been explored, and results were qualitatively identical.
It is important to note that the model only concentrates on describing the initial growth dynamics of the tumor within a tissue environment, which varies in checkpoint competence (such as p53 þ / þ , p53 þ /À, and p53À/À organisms, see Discussion). The checkpoints under consideration (e.g. p53) can induce cell cycle arrest and apoptosis in tumor cells and are only lost later in the course of progression (Blagosklonny, 2002; Kahlem et al., 2004) . Therefore, these initial tumor cells are assumed to have the same level of checkpoint competence as the normal tissue cells.
There are two quantities which are important for the analysis. These are the initial growth rate of the tumor and the mutation rate of the tumor cells. They will be explained in turn.
(i) The initial growth rate of the tumor is made up of two components. These are the production of tumor cells from healthy tissue, and the exponential growth of those tumor cells (clonal expansion). While production of tumor cells by healthy tissue is important for the initiation of tumor cell growth, the exponential growth term becomes dominant as clonal expansion takes off. As both processes are involved in the initiation of cancer, I consider the average time until a tumor reaches an arbitrary threshold size as a measure of how fast a tumor can develop. The longer this time, the slower the development of cancer. In terms of experimental data, it correlates with a lower fraction of animals which show a tumor by a defined time point. It is important to note that this growth phase only corresponds to the initial expansion phase, which leads to a first-stage and detectable tumor. While not included in the model explicitly, this initial growth is not assumed to go on. Instead, the tumor is likely to remain at a given small size until further mutations allow the cells to progress and expand further. In the model, this is dealt with by stopping the simulation once the tumor has reached this critical threshold size. (ii) Thus, once a tumor has been initiated and has grown to the threshold size, further progression requires the accumulation of additional carcinogenic mutations. This is influenced by the mutation rate of cells, m. The higher the mutation rate, the higher the chance that an additional carcinogenic mutation is created. In the model, the mutation rate of cells is given by m ¼ bru(1ÀZ)(1Àa)/(px þ 1).
The following sections will examine how checkpoint competence influences the initial tumor cell growth and the subsequent accumulation of further mutations. I will start by examining the basic tumor cell dynamics without taking into account tissue-tumor cell interactions. Then, I will examine how tissue-mediated tumor cell inhibition influences the results. As explained above, the analysis will concentrate on the effect of cell cycle arrest and senescence, captured in the parameter Z.
Basic dynamics of tumor initiation and progression
Here I consider how checkpoint competence influences initial tumor growth and the accumulation of carcinogenic mutations in the absence of tissue-mediated tumor cell inhibition (p ¼ 0). That is, the only effect of healthy tissue is to give rise to a transformed cell by mutation. The outcome depends on what can be called the 'cost of cell cycle arrest', and the 'cost of cell death ' (Komarova and Wodarz, 2003) , and is summarized in Figure 3 . The cost of cell cycle arrest represents the average duration for which cells remain in an arrested state (given by 1/g). The longer the duration of cell cycle arrest, the more the cell cycle becomes delayed, and the higher the fitness cost for the cells. On the other hand, the cost of cell death represents the fitness reduction of cells, which is brought about by the generation of lethal mutants. Lethality can arise from necrotic cell death, but in cancer apoptosis will play a very important role. The higher the probability that a mutant is lethal (higher value of a), the higher the cost of cell death. The behavior of the model depends on the relative magnitude of these costs.
If the cost of cell cycle arrest is significantly higher than the cost of cell death, a decrease in checkpoint competence correlates with faster initial tumor growth, and with an enhanced ability to accumulate further carcinogenic mutations (Figure 3) . The reason is that cells in checkpoint-deficient organisms avoid senescence, and this leads to faster cell division and a higher mutation rate. As the cost of cell cycle arrest is decreased relative to the cost of cell death (cells return to a dividing state faster and more mutations result in cell death), this picture changes (Figure 3 ). Now, a reduction in checkpoint competence can lead to a slower initial growth of tumor cells. That is, checkpoint-deficient organisms are expected to show a reduced incidence of tumors. The lower the cost of cell cycle arrest, and the higher the cost of cell death, the more pronounced this trend. The reason is as follows. The advantage gained from avoiding cell cycle arrest in checkpoint-deficient organisms is outweighed by the disadvantage of increased cell death in the absence of repair. Overall, this leads to a reduced initial growth rate of tumor cells in the checkpoint-deficient scenario. Note that the time it takes the tumor to reach the threshold size tends towards infinity as Z-1. This because for Z ¼ 1, genome surveillance is 100% efficient and no mutants are ever created. This is clearly unrealistic.
While a reduction in checkpoint competence can lead to a slower initial growth rate of the tumor cells in this parameter region, a reduction in checkpoint competence always results in a higher mutation rate of the tumor cells (Figure 3) , and thus in an enhanced ability of the tumor to progress. Therefore, if the cost of cell death is high compared to the cost of cell cycle arrest, the model gives rise to the counter-intuitive observation that a reduction in checkpoint competence can lead to the generation of fewer first-stage tumors during a defined time frame; however, the tumors which do arise are expected to accumulate further carcinogenic mutations faster and therefore have the potential to progress faster. It remains to be Figure 3 (a) Effect of the costs of cell cycle arrest and cell death on the relationship between checkpoint competence (probability to arrest upon damage, Z) and the time it takes the tumor to reach a critical size (first stage size). I vary the rate at which arrested cells return to a dividing state, g. The lower the value of g, the longer the duration of cell cycle arrest. If the duration of cell cycle arrest is long relative to the death rate of cells (g ¼ 0.1), a reduction of checkpoint competence results in a reduced time for the tumor to reach the critical size (faster growth). If duration of cell cycle arrest is shorter, this relationship changes: now a reduction in checkpoint competence leads to a longer time for the tumor to reach the critical size (slower growth rate). The shorter the duration of cell cycle arrest relative to the rate of cell death, the more pronounced this trend (compare g ¼ 1 and g ¼ 10). In all cases, the time it takes for the tumor to reach the critical size goes towards infinity for Z ¼ 1 because under this condition genome surveillance is 100% effective and no mutants are created. (b) The mutation rate of the tumor cells always increases with reduced checkpoint competence, regardless of the relative costs of cell cycle arrest and cell death. Parameter values were chosen as follows. r ¼ 2; r ¼ 2; u ¼ 0.3; a ¼ 0.9; b ¼ 10
Checkpoint genes, ageing, and cancer D Wodarz determined how relevant this result is. While these conditions could hold for checkpoint genes which are solely responsible for DNA repair, they might not hold for checkpoints which are responsible for apoptosis, or for both senescence and aopotosis (such as p53). If a reduction in the checkpoint leads to reduced apoptosis, cell death is not likely to be the dominant fitness cost.
Effect of tissue-mediated tumor cell inhibition
Now I examine how tissue-mediated tumor cell inhibition influences the effect of checkpoint competence on the initial growth rate of the tumor and the mutation rate of tumor cells. The dynamics depend on the degree with which healthy tissue exerts inhibitory activity on the tumor cells, p. This is shown in Figure 4 , and also summarized by time-series simulations in Figure 5 . First, assume that the tissue-mediated inhibitory activity is relatively small and lies below a threshold (small value of p). Now, the behavior of the model is identical to the one described in the last section. I concentrate on the parameter region in which a reduction in checkpoint competence leads to an increased initial growth rate of the tumor cells, and to 
Checkpoint genes, ageing, and cancer D Wodarz an increased mutation rate (shown again in Figure 4 for reference). In other words, senescence represents an important cost for the cells. As explained above, reduced checkpoint competence allows cancer cells to proceed through the cell cycle without delay following genomic alterations (Figure 5a) . Again, at values of Z close to 1, the time it takes the tumor to reach the threshold size becomes rapidly longer and goes to infinity for Z ¼ 1, because genomic surveillance is 100% efficient (Figure 4) .
As the rate of tumor cell inhibition, p, is increased, these patterns change (Figure 4) . Now, a reduction of checkpoint competence results in a slower growth rate of the tumor (summarized by a time-series graph in Figure 5b ). The higher the checkpoint competence, the faster the initial growth rate of the tumor. As the rate of tissue-mediated inhibition of cancer cells is increased further, the more pronounced this relationship becomes (Figure 4) . This is the same counter-intuitive result observed above, and is explained as follows in the current context. A checkpoint has two opposing effects on cancer cells in the model. On the one hand, it sends tumor cells into cell cycle arrest and this slows down tumor growth. On the other hand, it reduces the inhibitory effect exerted by tissue cells, and this enhances tumor growth. Tissue-mediated inhibitory effects are reduced because the tissue cells frequently enter cell cycle arrest, during which they do not function at normal levels. If tissue-mediated inhibition plays a sufficiently important role in the dynamics of tumor initiation (high values of p), the advantage gained by reduced tissue-mediated inhibition in the presence of a checkpoint outweighs the cost the cancer cells have to pay as a result of checkpoint competence. As before, we observe that, as the value of Z approaches 1, the time it takes for the tumor to grow to the threshold size goes towards infinity because genomic surveillance prevents the generation of any tumor cells (Figure 4) . In contrast to the rate of tumor growth, an increase in the level of tissue-mediated tumor cell inhibition does not change the relationship between checkpoint competence and the mutation rate of the cells (ability of the tumor to progress). Regardless of the value of p, a reduction in checkpoint competence is predicted to result in a faster rate of mutation (Figure 4) . Therefore while reduced checkpoint competence is expected to result in the establishment of fewer tumors within a given time frame, the tumors which do develop are predicted to progress faster. This is the same outcome as observed in the last section, but is brought about by a different mechanism.
The only case where these relationships do not hold is at very high rates of DNA damage (u-1). In this case, most tissue cells will be nonfunctional or dead and tumor cell inhibition is not a significant factor anymore. This parameter region is, however, biologically unrealistic because such a scenario would correspond to death of the organism as a result of senescence or tissue destruction.
While not considered explicitly, the same considerations should apply to checkpoints which induce apoptosis. Higher levels of apoptosis can reduce the number of tissue cells, and this can lead to a compromised ability of the tissue to inhibit tumor cells. If tissue-mediated inhibition of tumor cells is a sufficiently significant component in the dynamics of tumor initiation, then apoptosis deficiency can lead to reduced tumor incidence, but in faster progression of the tumors which do develop. Whether this argument holds depends on how exactly apoptosis influences tissue size and the process of ageing (Jansen-Durr, 2002; Campisi, 2003; Camplejohn et al., 2003; Gilhar et al., 2004) . 
Discussion
This paper investigated the relationship between checkpoint competence, senescence, and the development of cancer. Different relationships were found.
(i) The higher the checkpoint competence, the lower the rate of cancer incidence and progression, but the earlier the onset of ageing (level of senescence is higher in the face of DNA damage). Lower checkpoint competence prevents an early onset of ageing, but promotes cancers. This outcome is brought about by the following conditions. First, the advantage derived from avoiding cell cycle arrest upon damage must be higher than the cost derived from cell death in the absence of repair. In addition, it requires that tissue cells exert no or only little inhibitory activity on tumor cells. These arguments might only apply to checkpoints which induce cell cycle arrest, and not to checkpoints which induce apoptosis. (ii) A reduction in checkpoint competence can result both in fewer ageing symptoms and in fewer cancers; however, the cancers which do become established are characterized by accelerated progression. This is promoted by the following conditions (for a schematic explanation see Figure 6 ). First, it may occur because the cost derived from increased cell death in the absence of repair is higher than the benefit derived from avoiding cell cycle arrest upon damage. Whether this argument applies depends on the details of the checkpoint mediated activity, and requires that cell death (and thus apoptosis) occurs efficiently. However, a separate mechanism can lead to the same observation. It involves tissue-mediated tumor cell inhibition as a significant factor in the dynamics of tumor initiation. Reduced checkpoint competence prevents tissue ageing and preserves the inhibitory function. This in turn leads to the development of fewer tumors. In contrast, higher checkpoint competence promotes tissue ageing and compromises inhibitory function. In this parameter region, the advantage which the tumor cells gain from impaired inhibition outweighs the cost derived from the disruption of the tumor cell cycle; this leads to the generation of more cancers. This effect of tissue-mediated tumor cell inhibition is summarized by computer simulations in Figure 5 . Since this mechanism requires that checkpoint-induced ageing plays a dominant role in the dynamics of tissue cells, it is promoted by the occurrence of relatively high levels of DNA damage which can potentially trigger the checkpoints. It is unlikely to apply if DNA damage is a relatively rare event. This mechanism may also apply to the induction of apoptosis if apoptosis contributes to a tissue ageing and a decline of tissue function.
In the following, these notions will be discussed in the context of mice which have varying competence to mount p53 responses upon genomic damage.
A recent study has demonstrated that p53 might be an important factor which contributes to senescence and ageing (Donehower, 2002; Tyner et al., 2002) , and this has sparked much discussion (Kirkwood, 2002; Sharpless and DePinho, 2002) . Tyner et al. developed a genetically altered mouse that can express a truncated form of p53 which augments wild-type p53 activity. Survival of these super-p53 mice was compared to wild-type (p53 þ / þ ) animals as well as p53-deficient animals (p53À/ þ , p53À/À). The experiments demonstrated that p53 þ / þ mice showed best survival, followed by the super-p53 mice. The p53-deficient animals were characterized by even more reduced survival because of the early development of certain cancers. It turned out that the super-p53 animals had reduced survival compared to wild-type mice because they experienced an accelerated onset of ageing. On the other hand, tumor incidence in super-p53 mice was greatly reduced. These experiments support the notion that p53 activity represents a tradeoff between preventing senescence and preventing the development of cancer. This is one of the parameter regions observed in the model, and the conditions of the experiments are consistent with this parameter region. Two aspects are likely to be responsible. First, the study looked for the spontaneous development of tumors and did not induce them with carcinogenic agents. This means that, especially at relatively early ages of the mice, DNA Figure 6 Schematic summary of the counter-intuitive mathematical result regarding checkpoint competence and tumor incidence. Please note that this is not based on numerical simulation, but is a graphical summary to aid understanding. The relative tumor growth rate in a checkpoint-competent and -deficient scenario can depend on two basic parameters. These are the inhibition of tumor cells by the tissue microenvironment, p, and the cost of cell death, a, relative to the cost of cell cycle arrest, 1/g. At low rates of tumor cell inhibition, the tumor grows faster in checkpoint-deficient organisms. If the rate of inhibition is increased, the tumor grows faster in checkpoint-competent organisms. This is because, in checkpoint-competent organisms, tissue ages quicker and this compromises the ability of the tissue to exert inhibitory activity on tumor cells. If the cost of cell death in the absence of repair is increased relative to the cost of cell cycle arrest upon repair, checkpoint-competent organisms again show a faster tumor growth rate than checkpoint-deficient organisms, especially in the presence of high levels of DNA damage. This is because, in the absence of repair, high levels of damage result in too much cell death. As explained in the text, this mechanism is only likely to hold for checkpoints which are not responsible for apoptosis, and thus might have limited relevance damage and the induction of checkpoints are rare events in healthy tissue cells. This means that the amount of tissue-mediated tumor cell inhibition is not likely to differ significantly between p53 competent and p53 deficient mice during this phase. The only effect of p53 deficiency is to allow the tumor cells to progress faster through the cell cycle in the face of oncogenic mutations. Therefore, p53-deficient mice are expected to show an elevated onset of tumors during early life. In addition, it is possible that the cancers which developed in the p53-deficient mice are not significantly inhibited by tissue cells. The amount of tissue-mediated inhibition of tumor cells can vary between different tissues. In this context, it is interesting to note that the cancers which developed in p53-deficient animals in this study were specific cases, mostly sarcomas and lymphomas. Other cancers in which deletion of p53 is an important step were not observed to occur at elevated levels. In fact, lung cancers were observed in p53 competent but not in p53-deficient animals.
Another interesting study compared the rate of skin cancer initiation and progression in p53 þ / þ , p53 þ /À, and p53À/À mice (Kemp et al., 1993) . The rate of cancer initiation and progression was statistically similar in p53 þ / þ and p53 þ /À heterozygotes. Double knockout mice (p53À/À), however, showed a reduced incidence of paillomas compared to wild-type animals. On the other hand, the tumors which were generated in p53À/À mice were characterized by more rapid malignant progression compared to p53 þ / þ animals. This is the second type of behavior predicted by the model. The reason that this behavior is observed in the study by Kemp et al. could be as follows. First, the development of skin cancer is known to depend strongly on angiogenesis, and therefore inhibition of angiogenesis could ensure that tissue-mediated tumor cell inhibition is a significant force in the process of cancer initiation and progression. Moreover, in contrast to the study by Tyner et al., mice were treated with carcinogenic agents in order to induce tumors. This means that mice experience elevated levels of DNA damage and frequent induction of p53. This can result in elevated levels of tissue senescence in p53 competent animals, and this could result in reduced ability of tissue cells to display antitumor activity. Hence, tumors develop more often in p53 competent compared to p53-deficient mice. According to the model, another explanation for this outcome could be that in the absence of repair, the cost derived from the production of lethal mutants outweighs the benefit derived from avoiding repair and cell cycle arrest. It is, however, not clear whether this is a likely explanation. As p53 is also involved in the induction of apoptosis upon genomic damage or oncogenic mutations, it can be argued that p53-deficient organisms show reduced levels of apoptosis and cell death. Therefore, lethality in the absence of repair might not be a dominant factor. This paper has shown that the relationship between senescence, checkpoint competence, and the development of cancer can vary significantly depending on the details of the processes involved in carcinogenesis. In one parameter region, reduced checkpoint competence results in reduced senescence and a higher rate of cancer incidence and progression. In another parameter region, reduced checkpoint competence results both in reduced senescence and in a reduced cancer incidence. The tumors which do develop are, however, predicted to progress at a faster rate. Both types of relationships have been reported in experiments with mice which vary in their p53 competence. Outcomes depend on the details of the experimental study, consistent with the conditions derived from the mathematical models.
This work also has implications for understanding the pattern of cancer incidence in patients, which have a familial genetic defect in checkpoint genes. An interesting example is Li-Fraumeni syndrome, which is characterized by lack of functional p53 in every cell of the body (Evans and Lozano, 1997). Interestingly, patients develop only certain types of cancers, most importantly sarcomas. Although other types of cancers, such as colon cancer, also involve p53 inactivation as a crucial event in progression, they do not occur at elevated rates in Li-Fraumeni patients. According to the modeling results presented here, the exact details involved in the process of carcinogenesis can determine whether reduced p53 activity (and reduced checkpoint competence in general) leads to a higher incidence of cancers or not.
Further experimental studies with mice could address some of the theoretical notions described in this paper. First, it will be important to measure basic cell cycle parameters in early tumor cells (e.g. in skin tumors). These are the duration of cell cycle arrest and the amount of cell death occurring as a function of the degree of DNA damaged induced in p53 þ / þ , p53 þ / À, and p53À/À mice. This would provide insights into the relative magnitude of the costs derived from cell cycle arrest and cell death. In addition, the role of tissuemediated tumor cell inhibition could be explored by investigating the development of skin cancers in p53 þ / þ , p53 þ /À, and p53À/À mice under different circumstances, which vary in the amount of carcinogens applied. The higher the amount of carcinogens applied to the mice, the more often p53 will become induced, and the stronger the degree of tissue senescence. If tissue-mediated tumor cell inhibition is a dominant driving force, the model predicts that p53-deficient mice will show an elevated cancer incidence if no or small amounts of carcinogens are applied, while they will show reduced cancer incidence as the amount of carcinogen application is increased.
Materials and methods
Ordinary differential equations were used in order to examine the dynamics of initial tumor cell growth as a function of checkpoint competence and inhibitory activity exerted by healthy cells. The population of healthy tissue cells is assumed to be constant. The population of tumor cells is assumed to grow exponentially. The equations describe the change of the tumor cell population over time. The equations are written down and explained in the Results section. The model is explored by a combination of analytic methods and numerical simulations.
